Home » Newsletters » BioWorld Science

BioWorld Science

April 12, 2005

View Archived Issues

Oragenics develops manufacturing process for Mutacin 1140

Labedipinedilol A: a potential treatment for atherosclerosis

A novel vasopressin V1b receptor antagonist reduces aggressive behavior

NPY Y2 receptor is involved in PYY3-36-mediated appetite regulation / News in Context

CH-1504 in development at Chelsea Therapeutics for rheumatoid arthritis

Pfizer reviews recent developments

A transdermal testosterone patch improves androgen deficiency in women with POF / News in Context

Avigen discontinues AAV funding to focus on traditional pharmaceuticals

Pfizer to suspend Bextra in Europe, Canada

Phase II trial studies Ceflatonin in combination with Gleevec for CML

Abbott cleared to begin ZOMAXX II trial

Array BioPharma and Genentech expand oncology collaboration

Ligand exercises final option to buy down Ontak royalties

AVE-1330A effective against ceftazidime-resistant Enterobacteriaceae species

New phase I data on the safety and pharmacokinetics of PTC-124

BG-12 reduces symptom scores in moderate-severe psoriasis

AVE-4221 effective against methicillin and multidrug resistant strains of Staphylococcus aureus

XP-13512 shows promise in the treatment of PHN

Emtriva and Truvada set for Japanese launch

Oxypurinol reported to improve ejection fraction of CHF patients

BrachySil enters full development program for pancreatic cancer

Tracleer receives Japanese approval

Novel therapeutic agents for obesity reported by Schering-Plough

Recent patents disclose novel agents for the treatment of infectious diseases

New Japanese approval for Prograf

BLA filing for RotaTeq

Yondelis receives orphan drug designation for ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...